TriSalus Life Sciences (NASDAQ:TLSI) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report published on Tuesday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $10.00 price objective on the stock.

TLSI has been the topic of several other research reports. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $3.60 on Tuesday. The business’s 50 day moving average price is $4.14 and its 200 day moving average price is $4.96. The company has a market cap of $109.77 million, a price-to-earnings ratio of -1.45 and a beta of 0.56. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42.

Insider Buying and Selling

In other news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the acquisition, the insider now owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders purchased 70,012 shares of company stock valued at $281,235. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of TLSI. Wolverine Asset Management LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter valued at approximately $240,000. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $1,184,000. Duquesne Family Office LLC boosted its position in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter worth $66,000. Finally, MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.